• Mashup Score: 0

    May 25, 2023 — Boston Scientific Corporation announced data supporting use of the company’s key electrophysiology and cardiac rhythm management therapies, and the WATCHMAN FLX Left Atrial Appendage Closure (LAAC) Device. All data were presented at Heart Rhythm 2023, the annual meeting of the Heart Rhythm Society, held in New Orleans from May 19-21. Real-world outcomes from the EU-PORIA registry…

    Tweet Tweets with this article
    • @DAICeditor @BSCCardiology Additional real-world outcomes further demonstrate safety, efficacy and procedural reproducibility of the #FARAPULSE Pulsed Field #Ablation System: https://t.co/qoURMixDDb #HRS23

  • Mashup Score: 0

    May 26, 2023 — Atrial fibrillation, or AFib , is the most common heart rhythm problem, affecting millions of Americans and greatly increasing their risk of stroke and heart failure. For some with AFib, a catheter ablation is used to burn or freeze the precise area causing the problem to restore a normal heart rhythm. While this method is effective in treating AFib, the energy from the catheter…

    Tweet Tweets with this article
    • @DAICeditor @OSUWexMed An #electrophysiologist at The Ohio State University Wexner Medical Center helped develop a new device that gently diverts the #esophagus out of harm’s way, greatly improving safety: https://t.co/pTvEHDeQlZ #AFib #HRS23

  • Mashup Score: 0

    May 25, 2023 — Abbott announced late-breaking results from the AVEIR dual-chamber (DR) i2i Investigational Device Exemption (IDE) study, a large-scale study to assess the world’s first dual-chamber leadless pacemaker, showing that the leadless pacemaker met its three prespecified primary endpoints for safety and performance. The data further suggests that AVEIR DR could offer new benefits for…

    Tweet Tweets with this article
    • @DAICeditor @AbbottCardio Abbott's #AVEIR DR i2i IDE study is the industry's first prospective study on the safety and performance of the world's first dual-chamber #leadless #pacemaker: https://t.co/iqHX5lv4Ef #HRS23

  • Mashup Score: 0

    May 22, 2023 — Results from a pivotal clinical trial found a leadless pacemaker can deliver cardiac resynchronization therapy (CRT) among patients who were not able to be treated with conventional CRT and epicardial leads. The novel WiSE CRT system removes the possibility of lead complications and provides physicians with more freedom to target the pacing site within the endocardium of the…

    Tweet Tweets with this article
    • @DAICeditor Results from a pivotal clinical trial found a #leadless #pacemaker can deliver #cardiac #resynchronization therapy (#CRT) among patients who were not able to be treated with conventional CRT and #epicardial leads: https://t.co/MEi8YZvONP #HRS23

  • Mashup Score: 0

    May 22, 2023 — Findings from two new studies highlight the success of left bundle branch area pacing (LBBAP), or his-bundle pacing (HBP) as an alternative to biventricular pacing (BVP) for patients requiring cardiac resynchronization therapy (CRT). The results add to the growing body of evidence supporting new pacing methods and were presented as late-breaking clinical trials during Heart Rhythm…

    Tweet Tweets with this article
    • @DAICeditor Findings from two new studies highlight the success of left bundle branch area pacing (#LBBAP), or his-bundle pacing (#HBP) as an alternative to biventricular pacing (#BVP) for patients requiring cardiac resynchronization therapy (#CRT): https://t.co/B0DJFJVx8Y #HRS23

  • Mashup Score: 1

    May 22, 2023 — Boston Scientific Corporation announced data supporting use of the company’s key electrophysiology and cardiac rhythm management therapies, and the WATCHMAN FLX Left Atrial Appendage Closure (LAAC) Device. All data were presented at Heart Rhythm 2023, the annual meeting of the Heart Rhythm Society, held in New Orleans from May 19-21. Real-world outcomes from the EU-PORIA registry…

    Tweet Tweets with this article
    • @DAICeditor @BSCCardiology Results from #global #trial of the #POLARx #Cryoablation System meet safety and effectiveness endpoints: https://t.co/Et9ZxEOZbK #HRS23